Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Leukemia [Leukemia] NLMUID: 8704895"" wg kryterium: JN

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 6983
Tytuł:
Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms.
Autorzy:
Molenaar RJ; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA.; Department of Cell Biology & Histology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Thota S; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA.
Nagata Y; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Patel B; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA.
Clemente M; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA.
Przychodzen B; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA.
Hirsh C; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA.
Viny AD; Department of Medicine, Human Oncology & Pathogenesis, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA.
Hosano N; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA.
Bleeker FE; Department of Clinical Genetics, Academic Medical Center, University of Amsterdam, Meibergdreef 15, Amsterdam, The Netherlands.
Meggendorfer M; Munich Leukemia Laboratories, Max-Lebsche-Platz 31, Munich, Germany.
Alpermann T; Munich Leukemia Laboratories, Max-Lebsche-Platz 31, Munich, Germany.
Shiraishi Y; Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Chiba K; Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Tanaka H; Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
van Noorden CJ; Department of Cell Biology & Histology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Radivoyevitch T; Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA.
Carraway HE; Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA.
Makishima H; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA.
Miyano S; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Sekeres MA; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA.; Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA.
Ogawa S; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Haferlach T; Munich Leukemia Laboratories, Max-Lebsche-Platz 31, Munich, Germany.
Maciejewski JP; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 Nov; Vol. 29 (11), pp. 2134-42. Date of Electronic Publication: 2015 Apr 03.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Mutation*
Isocitrate Dehydrogenase/*genetics
Leukemia, Myeloid, Acute/*genetics
Myelodysplastic Syndromes/*genetics
Aged ; DNA-Binding Proteins/antagonists & inhibitors ; DNA-Binding Proteins/genetics ; Dioxygenases ; Female ; Humans ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Myelodysplastic Syndromes/mortality ; Nucleophosmin ; Prognosis ; Proto-Oncogene Proteins/antagonists & inhibitors ; Proto-Oncogene Proteins/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.
Autorzy:
Clappier E; Department of Genetics, Robert Debré Hospital, APHP, Paris, France.; Hematology University Institute, Paris-Diderot University, Paris, France.
Grardel N; Centre de Biologie Pathologie PM Degand, INSERM U837, Lille, France.
Bakkus M; Department of Hematology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Rapion J; EORTC Headquarters, Brussels, Belgium.
De Moerloose B; Department of Pediatric Hematology-Oncology, Ghent University Hospital, Ghent, Belgium.
Kastner P; Department of Cancer Biology, Institute of Genetics and Molecular and Cellular Biology (IGBMC), Illkirch, France.
Caye A; Department of Genetics, Robert Debré Hospital, APHP, Paris, France.; Hematology University Institute, Paris-Diderot University, Paris, France.
Vivent J; Department of Genetics, Robert Debré Hospital, APHP, Paris, France.; Hematology University Institute, Paris-Diderot University, Paris, France.
Costa V; Department of Pediatrics, Portuguese Oncology Institute, Porto, Portugal.
Ferster A; Department of Pediatric Onco-Hematology, Hôpital Universitaire des Enfants Reine Fabiola (ULB), Brussels, Belgium.
Lutz P; Department of Hematology, Hautepierre University Hospital, Strasbourg, France.
Mazingue F; Department of Pediatric Hematology-Oncology, Lille University Hospital, Lille, France.
Millot F; Department of Hematology, J Bernard University Hospital, Poitiers, France.
Plantaz D; Department of Pediatric Onco-Hematology, Grenoble University Hospital, La Tronche, France.
Plat G; Department of Pediatric Onco-Hematology, Purpan University Hospital, Toulouse, France.
Plouvier E; Department of Pediatric Onco-Hematology, Besançon University Hospital, Besançon, France.
Poirée M; Department of Pediatric Onco-Hematology, Nice University Hospital, Nice, France.
Sirvent N; Department of Pediatric Onco-Hematology, Montpellier University Hospital, Montpellier, France.
Uyttebroeck A; Department of Pediatrics, University Hospital Gasthuisberg, Leuven, Belgium.
Yakouben K; Department of Pediatric Hematology, Robert Debré Hospital, APHP, Paris, France.
Girard S; Hematology Laboratory, IHOP, Lyon, France.
Dastugue N; Hematology Laboratory, University Hospital Purpan, Toulouse, France.
Suciu S; EORTC Headquarters, Brussels, Belgium.
Benoit Y; Department of Pediatric Hematology-Oncology, Ghent University Hospital, Ghent, Belgium.
Bertrand Y; Department of Pediatric Hematology, IHOP and Claude Bernard University, Lyon, France.
Cavé H; Department of Genetics, Robert Debré Hospital, APHP, Paris, France.; Hematology University Institute, Paris-Diderot University, Paris, France.
Pokaż więcej
Corporate Authors:
European Organisation for Research and Treatment of Cancer, Children's Leukemia Group (EORTC-CLG)
Źródło:
Leukemia [Leukemia] 2015 Nov; Vol. 29 (11), pp. 2154-61. Date of Electronic Publication: 2015 Jun 08.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Gene Deletion*
Ikaros Transcription Factor/*genetics
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*genetics
Adolescent ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Male ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/mortality ; Prognosis ; Recurrence
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism.
Autorzy:
Atsaves V; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; GP Livanos and M Simou Laboratories, First Department of Critical Care Medicine and Pulmonary Services, Medical School of Athens University, 'Evangelismos' Hospital, Athens, Greece.
Zhang R; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ruder D; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pan Y; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Wuxi Medical School and Affiliated Hospital, Jiangnan University, Wuxi, China.
Leventaki V; Department of Pathology, Saint Jude Children's Hospital, Memphis, TN, USA.
Rassidakis GZ; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Pathology and Cytology, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden.
Claret FX; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Experimental Therapeutics Academic Program and Cancer Biology Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, USA.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 Nov; Vol. 29 (11), pp. 2162-72. Date of Electronic Publication: 2015 May 19.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Gene Expression Regulation, Neoplastic*
Lymphoma, Large-Cell, Anaplastic/*genetics
Proto-Oncogene Proteins c-akt/*genetics
Proto-Oncogene Proteins c-jun/*physiology
Receptor Protein-Tyrosine Kinases/*analysis
Transcription Factors/*physiology
Anaplastic Lymphoma Kinase ; Cell Line, Tumor ; Humans ; Promoter Regions, Genetic ; STAT3 Transcription Factor/physiology ; Transcription Factor AP-1/physiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
The stability of epigenetic factor ASXL1 is regulated through ubiquitination and USP7-mediated deubiquitination.
Autorzy:
Inoue D; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Nishimura K; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kozuka-Hata H; Medical Proteomics Laboratory, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Oyama M; Medical Proteomics Laboratory, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kitamura T; Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 Nov; Vol. 29 (11), pp. 2257-60. Date of Electronic Publication: 2015 Apr 03.
Typ publikacji:
Letter
MeSH Terms:
Ubiquitination*
Repressor Proteins/*physiology
Ubiquitin Thiolesterase/*physiology
HEK293 Cells ; HL-60 Cells ; Humans ; Tumor Suppressor Protein p53/physiology ; Ubiquitin-Specific Peptidase 7
Opinia redakcyjna
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Protracted dormancy of pre-leukemic stem cells.
Autorzy:
Ford AM; Centre for Evolution and Cancer, The Institute of Cancer Research, London, Sutton, UK.
Mansur MB; Centre for Evolution and Cancer, The Institute of Cancer Research, London, Sutton, UK.; Paediatric Haematology-Oncology Program, Research Centre, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
Furness CL; Centre for Evolution and Cancer, The Institute of Cancer Research, London, Sutton, UK.
van Delft FW; Newcastle Cancer Centre, NICR, Newcastle, UK.
Okamura J; Department of Pediatrics, National Kyushu Cancer Centre, Minami-ku, Japan.
Suzuki T; Department of Hematology, Saitama Cancer Centre, Ina, Japan.
Kobayashi H; Department of Hematology, Saitama Cancer Centre, Ina, Japan.
Kaneko Y; Department of Hematology, Saitama Cancer Centre, Ina, Japan.
Greaves M; Centre for Evolution and Cancer, The Institute of Cancer Research, London, Sutton, UK.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 Nov; Vol. 29 (11), pp. 2202-7. Date of Electronic Publication: 2015 May 28.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Neoplastic Stem Cells/*pathology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*pathology
Child, Preschool ; Exome ; Fusion Proteins, bcr-abl/genetics ; Gene Dosage ; Gene Rearrangement ; Genes, Immunoglobulin ; Humans ; Ikaros Transcription Factor/genetics ; Male ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Defining and treating high-risk multiple myeloma.
Autorzy:
Usmani SZ; Department of Hematologic Oncology, Blood Disorders and Bone Marrow Transplantation, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA.
Rodriguez-Otero P; Department of Hematology, Clínica Universidad de Navarra, CIMA, IDISNA, Navarra, Spain.
Bhutani M; Department of Hematologic Oncology, Blood Disorders and Bone Marrow Transplantation, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA.
Mateos MV; Department of Hematology, University hospital of Salamanca, IBSAL, Salamanca, Spain.
Miguel JS; Department of Hematology, Clínica Universidad de Navarra, CIMA, IDISNA, Navarra, Spain.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 Nov; Vol. 29 (11), pp. 2119-25. Date of Electronic Publication: 2015 Aug 12.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Multiple Myeloma/*therapy
Chromosome Aberrations ; Gene Expression Profiling ; Hematopoietic Stem Cell Transplantation ; Humans ; Multiple Myeloma/etiology ; Multiple Myeloma/genetics ; Multiple Myeloma/mortality
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.
Autorzy:
Kröger NM; Department of Stem Cell Transplantation, University Hospital, Hamburg, Germany.
Deeg JH; Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA, USA.
Olavarria E; Department of Hematology, Hospital of Navarra, Navarra Health Service, Pamplona, Spain.
Niederwieser D; Department of Haematology, Clinical Oncology and Hemostasiology, University of Leipzig, Leipzig, Germany.
Bacigalupo A; Ospedale San Martino, Genoa, Italy.
Barbui T; Research Foundation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.
Rambaldi A; Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy.
Mesa R; Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA.
Tefferi A; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Griesshammer M; Academic Department of Hematology and Oncology, Johannes Wesling Teaching Hospital, Hans-Nolte-Strasse 1, Minden, Germany.
Gupta V; Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Harrison C; Department of Haematology Guy's and St Thomas' NHS Foundation Trust, London, UK.
Alchalby H; Department of Stem Cell Transplantation, University Hospital, Hamburg, Germany.
Vannucchi AM; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Cervantes F; Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Robin M; Department of Hematology and Bone Marrow Transplantation, Saint Louis Hospital, Paris, France.
Ditschkowski M; Department of Bone Marrow Transplantation, WTZ, Comprehensive Cancer Centre, University Hospital Essen, Essen, Germany.
Fauble V; Mayo Clinic Cancer Center, Scottsdale, AZ, USA.
McLornan D; Department of Haematology Guy's and St Thomas' NHS Foundation Trust, London, UK.; Department of Haematological Medicine, King's College Hospital, London, UK.
Ballen K; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
Popat UR; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Passamonti F; Division of Hematology, Department of Medicine, University Hospital Ospedale di Circolo e Fondazione Macchi, Varese, Italy.
Rondelli D; University of Illinois Hospital & Health Sciences System and University of Illinois Cancer Center, Chicago, IL, USA.
Barosi G; Center for the Study of Myelofibrosis, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 Nov; Vol. 29 (11), pp. 2126-33. Date of Electronic Publication: 2015 Aug 21.
Typ publikacji:
Journal Article; Review; Systematic Review
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Primary Myelofibrosis/*therapy
Donor Selection ; Histocompatibility Testing ; Humans ; Primary Myelofibrosis/mortality ; Transplantation Conditioning ; Transplantation, Homologous
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia.
Autorzy:
Wedeh G; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.; LBPA CNRS UMR8113, Ecole Normale Supérieure de Cachan, Cachan, France.
Cerny-Reiterer S; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.
Eisenwort G; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.
Herrmann H; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.; Department of Radiotherapy, Medical University of Vienna, Vienna, Austria.
Blatt K; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Hadzijusufovic E; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.
Sadovnik I; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Müllauer L; Department of Pathology, Medical University of Vienna, Vienna, Austria.
Schwaab J; Third Medical Department, Division of Hematology, University of Heidelberg, Mannheim, Germany.
Hoffmann T; Research Institute of Molecular Pathology (IMP), Vienna, Austria.
Bradner JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Radia D; Guy's Hospital, Division of Clinical Haematology, London, UK.
Sperr WR; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.
Hoermann G; Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Reiter A; Third Medical Department, Division of Hematology, University of Heidelberg, Mannheim, Germany.
Horny HP; Institute of Pathology, Ludwig Maximilian University, Munich, Germany.
Zuber J; Research Institute of Molecular Pathology (IMP), Vienna, Austria.
Arock M; LBPA CNRS UMR8113, Ecole Normale Supérieure de Cachan, Cachan, France.
Valent P; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 Nov; Vol. 29 (11), pp. 2230-7. Date of Electronic Publication: 2015 Jun 09.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Epigenesis, Genetic*
Leukemia, Mast-Cell/*genetics
Nuclear Proteins/*physiology
Transcription Factors/*physiology
Antigens, CD/analysis ; Apoptosis/drug effects ; Azepines/pharmacology ; Cell Cycle Proteins ; Cell Line, Tumor ; Gene Expression Regulation, Leukemic ; Humans ; Leukemia, Mast-Cell/drug therapy ; Leukemia, Mast-Cell/pathology ; Nuclear Proteins/antagonists & inhibitors ; Nuclear Proteins/genetics ; Proto-Oncogene Proteins c-kit/physiology ; Receptors, Transferrin/analysis ; Tetraspanin 30/analysis ; Transcription Factors/antagonists & inhibitors ; Transcription Factors/genetics ; Tretinoin/pharmacology ; Triazoles/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.
Autorzy:
Wang W; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cortes JE; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lin P; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Khoury JD; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ai D; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tang Z; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tang G; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jorgensen JL; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Medeiros LJ; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hu S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 Nov; Vol. 29 (11), pp. 2263-6. Date of Electronic Publication: 2015 Apr 14.
Typ publikacji:
Letter
MeSH Terms:
Trisomy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Protein-Tyrosine Kinases/*antagonists & inhibitors
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Child ; Chromosomes, Human, Pair 8 ; Female ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality ; Male ; Middle Aged
SCR Disease Name:
Chromosome 8, trisomy
Opinia redakcyjna
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib.
Autorzy:
Jagannathan S; Division of Hematology and Oncology, The Vontz Center for Molecular Studies, University of Cincinnati College of Medicine, Cincinnati, OH, USA.; Division of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Abdel-Malek MA; Division of Hematology and Oncology, The Vontz Center for Molecular Studies, University of Cincinnati College of Medicine, Cincinnati, OH, USA.; Division of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Malek E; Division of Hematology and Oncology, The Vontz Center for Molecular Studies, University of Cincinnati College of Medicine, Cincinnati, OH, USA.; Division of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Vad N; Division of Hematology and Oncology, The Vontz Center for Molecular Studies, University of Cincinnati College of Medicine, Cincinnati, OH, USA.; Division of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Latif T; Division of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.; University of Cincinnati Cancer Institute, Cincinnati, OH, USA.
Anderson KC; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Driscoll JJ; Division of Hematology and Oncology, The Vontz Center for Molecular Studies, University of Cincinnati College of Medicine, Cincinnati, OH, USA.; Division of Hematology and Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.; University of Cincinnati Cancer Institute, Cincinnati, OH, USA.; Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 Nov; Vol. 29 (11), pp. 2184-91. Date of Electronic Publication: 2015 Jun 25.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Antineoplastic Agents/*pharmacology
Autophagy/*drug effects
Bortezomib/*pharmacology
Heat-Shock Proteins/*antagonists & inhibitors
Metformin/*pharmacology
Multiple Myeloma/*drug therapy
Animals ; Apoptosis/drug effects ; Cell Line, Tumor ; Drug Synergism ; Endoplasmic Reticulum Chaperone BiP ; Female ; Heat-Shock Proteins/physiology ; Humans ; Mice ; Phosphatidylinositol 3-Kinases/physiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Control of AC133/CD133 and impact on human hematopoietic progenitor cells through nucleolin.
Autorzy:
Bhatia S; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany.
Reister S; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany.
Mahotka C; Institute of Pathology, Heinrich Heine University, Düsseldorf, Germany.
Meisel R; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany.
Borkhardt A; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany.
Grinstein E; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 Nov; Vol. 29 (11), pp. 2208-20. Date of Electronic Publication: 2015 Jun 19.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antigens, CD/*physiology
Glycoproteins/*physiology
Hematopoietic Stem Cells/*physiology
Peptides/*physiology
Phosphoproteins/*physiology
RNA-Binding Proteins/*physiology
AC133 Antigen ; Antigens, CD/genetics ; Cells, Cultured ; Glycoproteins/genetics ; Humans ; Peptides/genetics ; Promoter Regions, Genetic ; beta Catenin/analysis ; beta Catenin/physiology ; Nucleolin
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.
Autorzy:
Morelli E; Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy.
Leone E; Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy.
Cantafio ME; Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy.
Di Martino MT; Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy.
Amodio N; Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy.
Biamonte L; Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy.
Gullà A; Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy.
Foresta U; Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy.
Pitari MR; Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy.
Botta C; Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy.
Rossi M; Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy.
Neri A; Department of Medical Sciences, University of Milan, Hematology 1, IRCCS Policlinico Foundation, Milan, Italy.
Munshi NC; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; VA Boston Healthcare System, West Roxbury, Boston, MA, USA.
Anderson KC; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Tagliaferri P; Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy.
Tassone P; Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy.; Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 Nov; Vol. 29 (11), pp. 2173-83. Date of Electronic Publication: 2015 May 19.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Interferon Regulatory Factors/*genetics
MicroRNAs/*physiology
Multiple Myeloma/*therapy
Animals ; Apoptosis ; Autophagy ; Cell Line, Tumor ; Cell Proliferation ; Genes, Tumor Suppressor/physiology ; Humans ; Male ; Mice ; Multiple Myeloma/pathology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy.
Autorzy:
Lachmann N; Reprogramming and Gene Therapy Group, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany.; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Czarnecki K; Reprogramming and Gene Therapy Group, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany.; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Brennig S; Reprogramming and Gene Therapy Group, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany.; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Phaltane R; Reprogramming and Gene Therapy Group, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany.; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Heise M; Reprogramming and Gene Therapy Group, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany.; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Heinz N; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Kempf H; Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Dilloo D; Department of Pediatric Hematology and Oncology, Center for Child and Adolescent Medicine, Rheinische Friedrich-Wilhelms University, Bonn, Germany.
Kaever V; Institute of Pharmacology, Research Core Unit Metabolomics, Hannover Medical School, Hannover, Germany.
Schambach A; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Heuser M; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Moritz T; Reprogramming and Gene Therapy Group, REBIRTH Cluster of Excellence, Hannover Medical School, Hannover, Germany.; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 Nov; Vol. 29 (11), pp. 2266-9. Date of Electronic Publication: 2015 Apr 29.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Genetic Therapy*
Antineoplastic Agents/*adverse effects
Bone Marrow/*drug effects
Cladribine/*adverse effects
Cytarabine/*adverse effects
Deoxycytidine Kinase/*genetics
Vidarabine/*analogs & derivatives
Cytidine Deaminase/physiology ; Drug Resistance, Neoplasm ; HL-60 Cells ; Hematopoietic Stem Cell Transplantation ; Humans ; Vidarabine/adverse effects
Raport
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.
Autorzy:
Zhao Q; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ahmed M; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tassev DV; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hasan A; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Pediatric Stem Cell Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kuo TY; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Pediatric Stem Cell Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Guo HF; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
O'Reilly RJ; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Pediatric Stem Cell Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cheung NK; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 Nov; Vol. 29 (11), pp. 2238-47. Date of Electronic Publication: 2015 May 19.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibody Affinity*
Leukemia/*therapy
Peptide Fragments/*immunology
Receptors, Antigen, T-Cell/*immunology
Single-Chain Antibodies/*therapeutic use
WT1 Proteins/*immunology
Animals ; Cell Line, Tumor ; Epitope Mapping ; Epitopes, T-Lymphocyte ; HLA-A2 Antigen/immunology ; Humans ; Killer Cells, Natural/immunology ; Male ; Mice ; Peptide Library
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia.
Autorzy:
Dorrance AM; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.; Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Neviani P; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.; Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Ferenchak GJ; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.; Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Huang X; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.; Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.; Nanoscale Science and Engineering Center for Affordable Nanoengineering of Polymeric Biomedical Devices, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.; Department of Biomedical Informatics, Ohio State University, Columbus, OH, USA.
Nicolet D; Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.; Alliance for Clinical Trials in Oncology Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.
Maharry KS; Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.; Alliance for Clinical Trials in Oncology Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.
Ozer HG; Department of Biomedical Informatics, Ohio State University, Columbus, OH, USA.
Hoellarbauer P; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.; Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Khalife J; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.; Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Hill EB; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.; Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Yadav M; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.; Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Bolon BN; Comparative Pathology and Mouse Phenotyping Shared Resource, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Lee RJ; Nanoscale Science and Engineering Center for Affordable Nanoengineering of Polymeric Biomedical Devices, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.; Department of Biomedical Informatics, Ohio State University, Columbus, OH, USA.
Lee LJ; Nanoscale Science and Engineering Center for Affordable Nanoengineering of Polymeric Biomedical Devices, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.; Department of Biomedical Informatics, Ohio State University, Columbus, OH, USA.
Croce CM; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.; Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.
Garzon R; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.; Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.; Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.
Caligiuri MA; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.; Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Bloomfield CD; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.; Comprehensive Cancer Center, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Marcucci G; Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 Nov; Vol. 29 (11), pp. 2143-53. Date of Electronic Publication: 2015 Jun 09.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Leukemia, Myeloid, Acute/*therapy
MicroRNAs/*antagonists & inhibitors
Nanoparticles/*administration & dosage
Neoplastic Stem Cells/*physiology
Animals ; DNA Methylation ; Humans ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/mortality ; Leukocyte Common Antigens/antagonists & inhibitors ; Mice ; Mice, Inbred C57BL ; MicroRNAs/physiology ; Neoplastic Stem Cells/drug effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Gene expression analysis of plasmablastic lymphoma identifies downregulation of B-cell receptor signaling and additional unique transcriptional programs.
Autorzy:
Chapman J; Division of Hematopathology, Department of Pathology, University of Miami, Miami, FL, USA.
Gentles AJ; Stanford Center for Cancer Systems Biology, Stanford University, Stanford, CA, USA.
Sujoy V; Division of Hematopathology, Department of Pathology, University of Miami, Miami, FL, USA.
Vega F; Division of Hematopathology, Department of Pathology, University of Miami, Miami, FL, USA.
Dumur CI; Virginia Commonwealth University, Richmond, VA, USA.
Blevins TL; Virginia Commonwealth University, Richmond, VA, USA.
Bernal-Mizrachi L; Derpartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Mosunjac M; Department of Pathology, Emory School of Medicine, Atlanta, GA, USA.
Pimentel A; Division of Hematology-Oncology, Department of Medicine, University of Miami and Sylvester Comprehensive Cancer Center, Miami, FL, USA.
Zhu D; Division of Hematology-Oncology, Department of Medicine, University of Miami and Sylvester Comprehensive Cancer Center, Miami, FL, USA.
Lossos IS; Division of Hematology-Oncology, Department of Medicine, University of Miami and Sylvester Comprehensive Cancer Center, Miami, FL, USA.; Department of Molecular and Cellular Pharmacology, University of Miami, Miami, FL, USA.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 Nov; Vol. 29 (11), pp. 2270-3. Date of Electronic Publication: 2015 Apr 24.
Typ publikacji:
Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Transcription, Genetic*
Plasmablastic Lymphoma/*genetics
Receptors, Antigen, B-Cell/*physiology
Adolescent ; Adult ; Child ; Child, Preschool ; DNA-Binding Proteins/genetics ; Down-Regulation ; Female ; Genes, myc ; Guanine Nucleotide Exchange Factors/genetics ; Humans ; Male ; Middle Aged ; Minor Histocompatibility Antigens ; Nuclear Proteins/genetics ; Signal Transduction
Raport
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Additional treatment with 2-Chloro-2-Deoxyadenosine during consolidation in children with high-risk acute myeloid leukemia does not improve survival.
Autorzy:
Creutzig U; Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany.
Dworzak MN; St Anna Children's Hospital and Children's Cancer Research Institute, Department of Pediatrics, Medical University of Vienna, Vienna, Austria.
Zimmermann M; Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany.
Bourquin JP; Pediatric Hematology/Oncology, University of Zurich, Zurich, Switzerland.
Gruhn B; Department of Pediatrics, Jena University Hospital, Jena, Germany.
Fleischhack G; Department of Pediatric Hematology-Oncology, University of Duisburg-Essen, Essen, Germany.
Graf N; Department of Pediatric Oncology and Hematology, Medical School, Saarland University, Homburg, Germany.
Klingebiel T; Pediatric Hematology, Oncology and Hemostaseology, University Children's Hospital of Frankfurt/Main, Goethe-University Frankfurt/Main, Frankfurt/Main, Germany.
Kremens B; Department of Pediatric Hematology-Oncology, University of Duisburg-Essen, Essen, Germany.
Lehrnbecher T; Pediatric Hematology, Oncology and Hemostaseology, University Children's Hospital of Frankfurt/Main, Goethe-University Frankfurt/Main, Frankfurt/Main, Germany.
von Neuhoff C; Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany.
Stackelberg AV; Department of Pediatric Oncology/Hematology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Starý J; Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Czech Pediatric Hematology Working Group (CPH), Prague, Czech Republic.
Reinhardt D; Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany.; Department of Pediatric Hematology-Oncology, University of Duisburg-Essen, Essen, Germany.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 Nov; Vol. 29 (11), pp. 2260-3. Date of Electronic Publication: 2015 Apr 14.
Typ publikacji:
Letter; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Cladribine/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Child ; Child, Preschool ; Humans ; Leukemia, Myeloid, Acute/mortality
Raport
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Protein kinase Cɛ inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients.
Autorzy:
Masselli E; Hematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.; Unit of Human Anatomy and Histology, Department of Biomedical, Biotechnological and Translational Sciences (S.Bi.Bi.T.), University of Parma, Parma, Italy.
Carubbi C; Unit of Human Anatomy and Histology, Department of Biomedical, Biotechnological and Translational Sciences (S.Bi.Bi.T.), University of Parma, Parma, Italy.
Gobbi G; Unit of Human Anatomy and Histology, Department of Biomedical, Biotechnological and Translational Sciences (S.Bi.Bi.T.), University of Parma, Parma, Italy.
Mirandola P; Unit of Human Anatomy and Histology, Department of Biomedical, Biotechnological and Translational Sciences (S.Bi.Bi.T.), University of Parma, Parma, Italy.
Galli D; Unit of Human Anatomy and Histology, Department of Biomedical, Biotechnological and Translational Sciences (S.Bi.Bi.T.), University of Parma, Parma, Italy.
Martini S; Unit of Human Anatomy and Histology, Department of Biomedical, Biotechnological and Translational Sciences (S.Bi.Bi.T.), University of Parma, Parma, Italy.
Bonomini S; Hematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
Crugnola M; Hematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
Craviotto L; Department of Clinical and Experimental Medicine, Hematology and BMT Unit, University of Parma, Parma, Italy.
Aversa F; Hematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.; Department of Clinical and Experimental Medicine, Hematology and BMT Unit, University of Parma, Parma, Italy.
Vitale M; Unit of Human Anatomy and Histology, Department of Biomedical, Biotechnological and Translational Sciences (S.Bi.Bi.T.), University of Parma, Parma, Italy.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 Nov; Vol. 29 (11), pp. 2192-201. Date of Electronic Publication: 2015 Jun 19.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Megakaryocytes/*cytology
Primary Myelofibrosis/*drug therapy
Protein Kinase C-epsilon/*antagonists & inhibitors
Protein Kinase Inhibitors/*pharmacology
Adult ; Aged ; Aged, 80 and over ; Cell Differentiation/drug effects ; Cell Proliferation/drug effects ; Female ; Humans ; Male ; Middle Aged ; Primary Myelofibrosis/etiology ; Primary Myelofibrosis/pathology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
BAALC potentiates oncogenic ERK pathway through interactions with MEKK1 and KLF4.
Autorzy:
Morita K; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Masamoto Y; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kataoka K; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Koya J; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kagoya Y; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yashiroda H; Laboratory of Protein Metabolism, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
Sato T; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.; Department of Transfusion Medicine, The University of Tokyo Hospital, Tokyo, Japan.
Murata S; Laboratory of Protein Metabolism, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
Kurokawa M; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.; Department of Cell Therapy and Transplantation, The University of Tokyo Hospital, Tokyo, Japan.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2015 Nov; Vol. 29 (11), pp. 2248-56. Date of Electronic Publication: 2015 Jun 08.
Typ publikacji:
Journal Article
MeSH Terms:
Extracellular Signal-Regulated MAP Kinases/*physiology
Kruppel-Like Transcription Factors/*physiology
Leukemia, Myeloid, Acute/*pathology
MAP Kinase Kinase Kinase 1/*physiology
MAP Kinase Signaling System/*physiology
Neoplasm Proteins/*physiology
Active Transport, Cell Nucleus ; Animals ; Cell Proliferation ; Humans ; Kruppel-Like Factor 4 ; Kruppel-Like Transcription Factors/antagonists & inhibitors ; Mice ; Protein Binding
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 6983

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies